Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:26:14.183Z.
Calculation as of: 2026-10-06T13:26:14.183Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
DiaMedica Therapeutics Inc.
Market Cap
$453.70M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$450.64M
Operating Cash Flow Yield
N/A
TTM Avg
28.93%
3Y Avg
28.93%
5Y Avg
28.93%
Market Cap
$447.43M
Operating Cash Flow Yield
N/A
TTM Avg
7.13%
3Y Avg
7.13%
5Y Avg
7.13%
Market Cap
$461.55M
Operating Cash Flow Yield
7.80%
TTM Avg
6.58%
3Y Avg
6.94%
5Y Avg
6.76%
Market Cap
$468.31M
Operating Cash Flow Yield
6.30%
TTM Avg
6.70%
3Y Avg
7.02%
5Y Avg
5.84%
Market Cap
$471.57M
Operating Cash Flow Yield
0.51%
TTM Avg
0.89%
3Y Avg
1.82%
5Y Avg
1.82%
Market Cap
$478.54M
Operating Cash Flow Yield
N/A
TTM Avg
4.04%
3Y Avg
4.04%
5Y Avg
4.04%
Market Cap
$428.16M
Operating Cash Flow Yield
N/A
TTM Avg
1.96%
3Y Avg
1.96%
5Y Avg
1.96%
Market Cap
$481.33M
Operating Cash Flow Yield
N/A
TTM Avg
18.97%
3Y Avg
18.89%
5Y Avg
14.32%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $453.70M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | N/A | 28.93% | 28.93% | 28.93% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | 7.13% | 7.13% | 7.13% |
| Kamada Ltd. (KMDA)vs › | $461.55M | 7.80% | 6.58% | 6.94% | 6.76% |
| NRC Health (NRC)vs › | $468.31M | 6.30% | 6.70% | 7.02% | 5.84% |
| Cerus Corporation (CERS)vs › | $471.57M | 0.51% | 0.89% | 1.82% | 1.82% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 4.04% | 4.04% | 4.04% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | 1.96% | 1.96% | 1.96% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | 18.97% | 18.89% | 14.32% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
